Anafiltamig - CAS 3009026-69-8

Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E, and MS4A1. It consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv arm targeting CD3E and MS4A1. Anafiltamig can simultaneously bridge T cells and B cells, thus activating T cells to selectively kill B-cell tumors. This compound is applicable for research on B-cell malignancies, such as non-Hodgkin lymphoma.

Others, Immunology/Inflammation related, Integrin

Immunology/Inflammation, Cytoskeletal Signaling, Others

3009026-69-8

-20°C

Ice Packs

Inhibitory Antibodies